Bliss GVS Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹313 crore and net profit of ₹53 crore for the September 2026 quarter.
Bliss GVS Pharma (NSE: BLISSGVS-BE) closed at ₹640.55 on 20 Nov 2026. Its market capitalisation is ₹6,814 crore and it trades at 41.9 times earnings.
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.